Ouro Medicines Reports Q1 Revenue of €6.5M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Reports Q1 revenue EUR 6.5M vs. EUR 75.0M last year. The year-over-year decrease in revenue was primarily driven by the deferred income related to the Gilead drug discovery platform being fully released in revenue at the end of 2025. "Having joined the company just one year ago, I'm thrilled with our progress. I am looking forward to consummating our partnership with Gilead and adding Ouro Medicines' talented team and its portfolio of programs to our Company," said CEO Henry Gosebruch.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
